Bhatia et al. [66] designed a STEAP1-targeted CAR T cell therapy with high antigen specificity (Fig. 2L), finding that STEAP1 CAR T cells showed reactivity at low antigen density, anti-tumor activity in mPCa models, and safety in human STEAP1 knock-in mouse models. Here, STEAP1 is linked to neoplasm.